落基山斑疹傷寒立克次體IgG免疫熒光玻片

Rickettsia rickettsii IgG IFA Kit

廣州健侖生物科技有限公司

主要用途：用于檢測(cè)人血清中的落基山斑疹傷寒立克次體IgG抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

落基山斑疹傷寒立克次體IgG免疫熒光玻片

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

論文作者之一、加州索爾克生物研究所的胡安·卡洛斯·魯茲皮蘇阿-貝爾莫特說：“在老鼠身上進(jìn)行的研究表明，這一過程迅速且安全，而且，這一方法繞過了在對(duì)人類細(xì)胞進(jìn)行重組用于治療和再生目的方面長(zhǎng)期存在的障礙。”
由誘導(dǎo)多能干細(xì)胞(iPS)產(chǎn)生的血細(xì)胞往往不能植入器官或骨髓中，而且也有可能引發(fā)腫瘤產(chǎn)生;而研究人員開發(fā)的這種名為“間接譜系轉(zhuǎn)化”的新技術(shù)耗時(shí)僅需兩周，也不會(huì)生成腫瘤，同時(shí)，以前的研究表明，這一新技術(shù)可被用來生成人類的血管細(xì)胞。
研究的主要作者、薩爾克研究所的研究員伊格納西奧·桑喬-馬丁內(nèi)斯說：“我們并沒有讓皮膚細(xì)胞退回到干細(xì)胞狀態(tài)，而是利用新技術(shù)，讓皮膚細(xì)胞忘記了自己是什么，然后讓其轉(zhuǎn)化為我們所需要的細(xì)胞類型。在研究中，我們就讓其成功地轉(zhuǎn)化為了白血球。而且，誘導(dǎo)細(xì)胞失去記憶并引導(dǎo)其‘變身’為新細(xì)胞只需兩個(gè)生物分子。”
在研究中，科學(xué)家們借用新技術(shù)，將一個(gè)名為SOX2的分子變得具有可塑性，也就是讓其失去自己是某種特殊細(xì)胞類型的記憶，隨后，研究人員讓名為miRNA125b的遺傳因子，誘導(dǎo)細(xì)胞轉(zhuǎn)變成白血球。
目前，研究人員正在進(jìn)行毒理學(xué)、細(xì)胞移植、預(yù)臨床研究和臨床研究之前的概念驗(yàn)證等研究。他們表示，研究讓他們朝著利用干細(xì)胞移植治療人類疾病又邁近了一步。

Juan Carlos Luz Pissoua-Belmot, a co-author of the Salk Institute for Biology in California, said: "Studies conducted in mice have shown that this process is rapid and safe, and that this The approach bypasses the long-standing barrier in the reorganization of human cells for therapeutic and regenerative purposes. "
The blood cells produced by induced pluripotent stem cells (iPS) are often not implanted in organs or bone marrow, and may also cause tumorigenesis; while the newly developed new technique called "indirect lineage transformation" developed by researchers takes only two Weeks, will not generate tumors, the same time, previous studies have shown that this new technology can be used to generate human vascular cells.
The main author of the study, Ignacio Sancho Martínez, a researcher at the Salk Institute, said: "Instead of allowing skin cells to return to the stem cell state, we use new techniques that allow skin cells to forget that they are What and then let it be transformed into the type of cell we need. In the latest research, we successfully transformed it into white blood cells.Moreover, only two organisms are required to induce cells to lose their memory and lead them to 'transform themselves' into new cells molecular."
In the latest study, scientists borrowed new technology to make a molecule called SOX2 plastic, that is, letting it lose its memory as a particular type of cell. The researchers then led a genetic study called miRNA125b, Induce cells to turn into white blood cells.
Currently, researchers are conducting toxicology, cell transplantation, pre-clinical studies and proof-of-concept studies prior to clinical studies. They said the latest research has taken them one step closer to using stem cell transplantation to treat human disease.